220 related articles for article (PubMed ID: 1681782)
21. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
22. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study.
Burn DJ; Brooks DJ
Neurology; 1993 Mar; 43(3 Pt 1):552-6. PubMed ID: 8451000
[TBL] [Abstract][Full Text] [Related]
23. Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia.
Furukawa Y; Nygaard TG; Gütlich M; Rajput AH; Pifl C; DiStefano L; Chang LJ; Price K; Shimadzu M; Hornykiewicz O; Haycock JW; Kish SJ
Neurology; 1999 Sep; 53(5):1032-41. PubMed ID: 10496263
[TBL] [Abstract][Full Text] [Related]
24. 6-[18F]fluoro-L-dopa uptake and [76Br]bromolisuride binding in the excitotoxically lesioned caudate-putamen of nonhuman primates studied using positron emission tomography.
Hantraye P; Loc'H C; Maziere B; Khalili-Varasteh M; Crouzel C; Fournier D; Yorke JC; Stulzaft O; Riche D; Isacson O
Exp Neurol; 1992 Feb; 115(2):218-27. PubMed ID: 1531196
[TBL] [Abstract][Full Text] [Related]
25. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
26. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.
Otsuka M; Ichiya Y; Kuwabara Y; Hosokawa S; Sasaki M; Yoshida T; Fukumura T; Masuda K; Kato M
J Neurol Sci; 1996 Mar; 136(1-2):169-73. PubMed ID: 8815166
[TBL] [Abstract][Full Text] [Related]
27. Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography.
Piccini P; de Yebenez J; Lees AJ; Ceravolo R; Turjanski N; Pramstaller P; Brooks DJ
Arch Neurol; 2001 Nov; 58(11):1846-51. PubMed ID: 11708994
[TBL] [Abstract][Full Text] [Related]
28. Age and severity of nigrostriatal damage at onset of Parkinson's disease.
De La Fuente-Fernández R; Lim AS; Sossi V; Adam MJ; Ruth TJ; Calne DB; Stoessl AJ; Lee CS
Synapse; 2003 Feb; 47(2):152-8. PubMed ID: 12454953
[TBL] [Abstract][Full Text] [Related]
29. Clinical heterogeneity of dopa-responsive dystonia: PET observations.
Takahashi H; Snow BJ; Nygaard TG; Calne DB
Adv Neurol; 1993; 60():586-90. PubMed ID: 8420195
[TBL] [Abstract][Full Text] [Related]
30. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
[TBL] [Abstract][Full Text] [Related]
31. [A case of familial juvenile dystonia-parkinsonism: 18F-6-fluorodopa and 18F-fluoro-2-deoxyglucose PET study].
Hanakawa T; Fukuyama H; Akiguchi I; Kato M; Kimura J; Shibasaki H
Rinsho Shinkeigaku; 1996 May; 36(5):655-60. PubMed ID: 8905984
[TBL] [Abstract][Full Text] [Related]
32. Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism.
Otsuka M; Ichiya Y; Hosokawa S; Kuwabara Y; Tahara T; Fukumura T; Kato M; Masuda K; Goto I
J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):898-904. PubMed ID: 1744644
[TBL] [Abstract][Full Text] [Related]
33. Striatal function in normal aging: implications for Parkinson's disease.
Sawle GV; Colebatch JG; Shah A; Brooks DJ; Marsden CD; Frackowiak RS
Ann Neurol; 1990 Dec; 28(6):799-804. PubMed ID: 2126684
[TBL] [Abstract][Full Text] [Related]
34. A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
Gallagher CL; Christian BT; Holden JE; Dejesus OT; Nickles RJ; Buyan-Dent L; Bendlin BB; Harding SJ; Stone CK; Mueller B; Johnson SC
Mov Disord; 2011 Sep; 26(11):2032-8. PubMed ID: 21638324
[TBL] [Abstract][Full Text] [Related]
35. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease.
Menza MA; Mark MH; Burn DJ; Brooks DJ
J Neuropsychiatry Clin Neurosci; 1995; 7(2):176-9. PubMed ID: 7626960
[TBL] [Abstract][Full Text] [Related]
36. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease.
Broussolle E; Dentresangle C; Landais P; Garcia-Larrea L; Pollak P; Croisile B; Hibert O; Bonnefoi F; Galy G; Froment JC; Comar D
J Neurol Sci; 1999 Jul; 166(2):141-51. PubMed ID: 10475108
[TBL] [Abstract][Full Text] [Related]
37. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder.
Ernst M; Zametkin AJ; Matochik JA; Pascualvaca D; Jons PH; Cohen RM
Am J Psychiatry; 1999 Aug; 156(8):1209-15. PubMed ID: 10450262
[TBL] [Abstract][Full Text] [Related]
38. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.
Sawle GV; Playford ED; Brooks DJ; Quinn N; Frackowiak RS
Brain; 1993 Aug; 116 ( Pt 4)():853-67. PubMed ID: 8353712
[TBL] [Abstract][Full Text] [Related]
39. Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia.
Calne DB; de la Fuente-Fernández R; Kishore A
J Neural Transm Suppl; 1997; 50():47-52. PubMed ID: 9120424
[TBL] [Abstract][Full Text] [Related]
40. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease.
Rinne JO; Bergman J; Ruottinen H; Haaparanta M; Eronen E; Oikonen V; Sonninen P; Solin O
Synapse; 1999 Feb; 31(2):119-24. PubMed ID: 10024008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
